-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Evolent Health, Lowers Price Target to $5

Benzinga·02/26/2026 19:12:41
Listen to the news
UBS analyst Kevin Caliendo maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $10 to $5.